Cargando…

Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease

BACKGROUND: This study investigated plasma biomarkers for neuroinflammation associated with Alzheimer’s disease (AD) in subjects with preclinical AD compared to healthy elderly. How these biomarkers behave in patients with AD, compared to healthy elderly is well known, but determining these in subje...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prins, Samantha, de Kam, Marieke L., Teunissen, Charlotte E., Groeneveld, Geert Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347121/ https://www.ncbi.nlm.nih.gov/pubmed/35922871 http://dx.doi.org/10.1186/s13195-022-01051-2

Ejemplares similares

A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation
por: Prins, Samantha, et al.
Publicado: (2021)

Inflammatory biomarkers in Alzheimer's disease plasma
por: Morgan, Angharad R., et al.
Publicado: (2019)

Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease
por: Yu, Xianfeng, et al.
Publicado: (2023)

Concatenating plasma p-tau to Alzheimer’s disease
por: Tijms, Betty M, et al.
Publicado: (2021)

Editorial: Biomarkers of Alzheimer’s Disease: The Present and the Future
por: Lehmann, Sylvain, et al.
Publicado: (2016)

The ultraviolet B inflammation model: Postinflammatory hyperpigmentation and validation of a reduced UVB exposure paradigm for inducing hyperalgesia in healthy subjects
por: Siebenga, Pieter S., et al.
Publicado: (2019)

Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
por: Stockmann, Julia, et al.
Publicado: (2020)

Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2023)

The plasma peptides of Alzheimer’s disease
por: Florentinus-Mefailoski, Angelique, et al.
Publicado: (2021)

Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
por: Stockmann, Julia, et al.
Publicado: (2021)

No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model
por: Baakman, Anne Catrien, et al.
Publicado: (2019)

Onset of Preclinical Alzheimer Disease in Monozygotic Twins
por: Konijnenberg, Elles, et al.
Publicado: (2021)

Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy Subjects
por: van Esdonk, Michiel J., et al.
Publicado: (2018)

Utility of Animal Models to Understand Human Alzheimer’s Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals
por: Qin, Tian, et al.
Publicado: (2020)

Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease
por: Jonaitis, Erin M, et al.
Publicado: (2023)

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective Na(V)1.8 Inhibitor, in Healthy Male Adults
por: Hijma, Hemme J, et al.
Publicado: (2021)

Biomarkers and Tools for Predicting Alzheimer’s Disease in the Preclinical Stage
por: Li, Tao-Ran, et al.
Publicado: (2022)

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
por: Verberk, Inge M. W., et al.
Publicado: (2018)

GPS driving: a digital biomarker for preclinical Alzheimer disease
por: Bayat, Sayeh, et al.
Publicado: (2021)

Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease
por: Wang, Xiaoqi, et al.
Publicado: (2020)

Effects of Mexiletine and Lacosamide on Nerve Excitability in Healthy Subjects: A Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study
por: Ruijs, Titia Q., et al.
Publicado: (2022)

Plasma lipocalin-2 levels in the preclinical stage of Alzheimer's disease
por: Eruysal, Emily, et al.
Publicado: (2019)

Plasma Biomarkers of Alzheimer’s Disease in African Americans
por: Deniz, Kaancan, et al.
Publicado: (2021)

Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double‐blind placebo‐controlled cross‐over study
por: Ruijs, Titia Q., et al.
Publicado: (2022)

Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease
por: Younes, Laurent, et al.
Publicado: (2019)

The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
por: Hansson, Oskar, et al.
Publicado: (2022)

Plasma biomarker profiles in autosomal dominant Alzheimer’s disease
por: Johansson, Charlotte, et al.
Publicado: (2023)

Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?
por: Del Campo Milan, Marta, et al.
Publicado: (2015)

Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society
por: Erickson, Claire M., et al.
Publicado: (2022)

Plasma p-tau217: from ‘new kid’ to most promising candidate for Alzheimer’s disease blood test
por: Teunissen, Charlotte E, et al.
Publicado: (2020)

Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?
por: den Haan, Jurre, et al.
Publicado: (2019)

Virtual disclosure of preclinical Alzheimer's biomarkers: Preliminary experiences
por: Erickson, Claire M., et al.
Publicado: (2021)

The association of angiotensin-converting enzyme with biomarkers for Alzheimer’s disease
por: Jochemsen, Hadassa M, et al.
Publicado: (2014)

Emerging Electroencephalographic Biomarkers to Improve Preclinical to Clinical Translation in Alzheimer’s Disease
por: Cope, Zackary A., et al.
Publicado: (2022)

The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease
por: Morrison, Cassandra, et al.
Publicado: (2023)

Acute response to cholinergic challenge predicts long‐term response to galantamine treatment in patients with Alzheimer's disease
por: Baakman, Anne Catrien, et al.
Publicado: (2022)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

The preservation of right cingulum fibers in subjective cognitive decline of preclinical phase of Alzheimer’s disease
por: Sun, Yu, et al.
Publicado: (2023)

Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing
por: Ketchum, Fred B., et al.
Publicado: (2022)

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_um0goq4tald3r6k3dpfuifpg2p